These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Current status of selegiline as a neuroprotective agent in Parkinson's disease. Olanow CW, Mytilineou C, Tatton W. Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720 [No Abstract] [Full Text] [Related]
15. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. Dunkel P, Chai CL, Sperlágh B, Huleatt PB, Mátyus P. Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814 [Abstract] [Full Text] [Related]
19. Drug Insight: new drugs in development for Parkinson's disease. Colosimo C, Fabbrini G, Berardelli A. Nat Clin Pract Neurol; 2006 Nov; 2(11):600-10. PubMed ID: 17057747 [Abstract] [Full Text] [Related]
20. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Miller RG, Mitchell JD, Lyon M, Moore DH. Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806 [Abstract] [Full Text] [Related] Page: [Next] [New Search]